Terms: = Thyroid cancer AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK AND Prognosis
65 results:
1. AKR1C3 silencing inhibits autophagy-dependent glycolysis in thyroid cancer cells by inactivating erk signaling.
Gao Y; Tao W; Wang S; Duan R; Zhang Z
Drug Dev Res; 2024 Feb; 85(1):e22142. PubMed ID: 38349266
[TBL] [Abstract] [Full Text] [Related]
2. thyroid dysfunction caused by exposure to environmental endocrine disruptors and the underlying mechanism: A review.
He J; Xu J; Zheng M; Pan K; Yang L; Ma L; Wang C; Yu J
Chem Biol Interact; 2024 Mar; 391():110909. PubMed ID: 38340975
[TBL] [Abstract] [Full Text] [Related]
3. Exosomal miR-361-3p promotes the viability of breast cancer cells by targeting ETV7 and BATF2 to upregulate the PAI-1/erk pathway.
Li Y; Fan L; Yan A; Ren X; Zhao Y; Hua B
J Transl Med; 2024 Jan; 22(1):112. PubMed ID: 38282047
[TBL] [Abstract] [Full Text] [Related]
4. CMTM 6 promotes the development of thyroid cancer by inhibiting NIS activity through activating the MAPK signaling pathway.
Chen X; Shen H; Liu H; Tan L; Zhang N
Funct Integr Genomics; 2024 Jan; 24(1):10. PubMed ID: 38221563
[TBL] [Abstract] [Full Text] [Related]
5. SLC35A2 expression drives breast cancer progression via erk pathway activation.
Yang X; Tao Y; Xu Y; Cai W; Shao Q
FEBS J; 2024 Apr; 291(7):1483-1505. PubMed ID: 38143314
[TBL] [Abstract] [Full Text] [Related]
6. Characterization of the genomic alterations in poorly differentiated thyroid cancer.
Lee Y; Moon S; Seok JY; Lee JH; Nam S; Chung YS
Sci Rep; 2023 Nov; 13(1):19154. PubMed ID: 37932340
[TBL] [Abstract] [Full Text] [Related]
7. Circular RNAs: characteristics, functions, mechanisms, and potential applications in thyroid cancer.
Wu M; Yuan H; Zou W; Xu S; Liu S; Gao Q; Guo Q; Han Y; An X
Clin Transl Oncol; 2024 Apr; 26(4):808-824. PubMed ID: 37864677
[TBL] [Abstract] [Full Text] [Related]
8. Tetraspanin 1 regulates papillary thyroid tumor growth and metastasis through c-Myc-mediated glycolysis.
Han J; Xie C; Liu B; Wang Y; Pang R; Bi W; Sheng R; He G; Kong L; Yu J; Ding Z; Chen L; Jia J; Zhang J; Nie C
Cancer Sci; 2023 Dec; 114(12):4535-4547. PubMed ID: 37750019
[TBL] [Abstract] [Full Text] [Related]
9. [Clinicopathological features of thyroid-like low-grade nasopharyngeal papillary adenocarcinoma].
Zhu M; Li J; Zheng WH; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2023 Aug; 52(8):820-826. PubMed ID: 37527987
[No Abstract] [Full Text] [Related]
10. Clinical characteristics and prognostic analysis of SMARCA4-deficient non-small cell lung cancer.
Liang X; Gao X; Wang F; Li S; Zhou Y; Guo P; Meng Y; Lu T
Cancer Med; 2023 Jul; 12(13):14171-14182. PubMed ID: 37184108
[TBL] [Abstract] [Full Text] [Related]
11. RNF125 attenuates hepatocellular carcinoma progression by downregulating SRSF1-erk pathway.
Feng Z; Ke S; Wang C; Lu S; Xu Y; Yu H; Li Z; Yin B; Li X; Hua Y; Qian B; Bai M; Fu Y; Zhang Y; Wu Y; Ma Y
Oncogene; 2023 Jun; 42(24):2017-2030. PubMed ID: 37142680
[TBL] [Abstract] [Full Text] [Related]
12. TESC promotes differentiated thyroid cancer development by activating erk and weakening NIS and radioiodine uptake.
Guo Y; Cai Y; Song F; Zhu L; Hu Y; Liu Y; Ma W; Ge J; Zeng Q; Ding L; Li L; Zheng G; Ge M
Endocrine; 2023 Sep; 81(3):503-512. PubMed ID: 37020077
[TBL] [Abstract] [Full Text] [Related]
13. RNF150 suppresses papillary thyroid carcinoma with ASK1 ubiquitination presenting a direct target via inactivating p38 signaling axis.
Deng W; Wu J; Zheng W; Wang Q; Li D; Kuang H
Cell Biol Int; 2023 Jul; 47(7):1198-1208. PubMed ID: 36950779
[TBL] [Abstract] [Full Text] [Related]
14. Overexpression of the pro-protein convertase furin predicts prognosis and promotes papillary thyroid carcinoma progression and metastasis through RAF/MEK signaling.
Poyil PK; Siraj AK; Padmaja D; Parvathareddy SK; Diaz R; Thangavel S; Begum R; Haqawi W; Al-Mohanna FH; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Mol Oncol; 2023 Jul; 17(7):1324-1342. PubMed ID: 36799665
[TBL] [Abstract] [Full Text] [Related]
15. N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways.
Wang J; Yu H; Dong W; Zhang C; Hu M; Ma W; Jiang X; Li H; Yang P; Xiang D
Gastroenterology; 2023 May; 164(6):990-1005. PubMed ID: 36764493
[TBL] [Abstract] [Full Text] [Related]
16. A novel methuosis inducer DZ-514 possesses antitumor activity via activation of ROS-MKK4-p38 axis in triple negative breast cancer.
Wang L; Mi D; Hu J; Liu W; Zhang Y; Wang C; Chen Y; Chen C
Cancer Lett; 2023 Feb; 555():216049. PubMed ID: 36608865
[TBL] [Abstract] [Full Text] [Related]
17. SLP-2 regulates the generation of reactive oxygen species and the erk pathway to promote papillary thyroid carcinoma motility and angiogenesis.
Chen J; Wang D; Xu R; Yao T; Guo Y; Liu Q; Yang E; Wu Z; Xu Z
Tissue Cell; 2023 Feb; 80():101997. PubMed ID: 36527788
[TBL] [Abstract] [Full Text] [Related]
18. cancer-associated fibroblasts facilitate premetastatic niche formation through lncRNA SNHG5-mediated angiogenesis and vascular permeability in breast cancer.
Zeng H; Hou Y; Zhou X; Lang L; Luo H; Sun Y; Wan X; Yuan T; Wang R; Liu Y; Tang R; Cheng S; Xu M; Liu M
Theranostics; 2022; 12(17):7351-7370. PubMed ID: 36438499
[No Abstract] [Full Text] [Related]
19. Pseudoangiosarcomatous squamous cell carcinoma: a rare subtype of squamous cell carcinoma that needs to be differentiated from angiosarcoma and has a poor prognosis.
Zhan Y; Wan H; Wu L; Ge X; Xie X; Wu L; Cai Y
Cell Mol Biol (Noisy-le-grand); 2022 Jun; 68(6):62-66. PubMed ID: 36227677
[TBL] [Abstract] [Full Text] [Related]
20. An integrative pan cancer analysis of RET aberrations and their potential clinical implications.
Zhou L; Li J; Zhang X; Xu Z; Yan Y; Hu K
Sci Rep; 2022 Aug; 12(1):13913. PubMed ID: 35978072
[TBL] [Abstract] [Full Text] [Related]
[Next]
